Effect of Intermittent or Continuous Feed on Muscle Wasting in Critical Illness: A Phase 2 Clinical Trial.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
07 2020
Historique:
received: 25 11 2019
revised: 09 03 2020
accepted: 15 03 2020
pubmed: 6 4 2020
medline: 22 5 2021
entrez: 6 4 2020
Statut: ppublish

Résumé

Acute skeletal muscle wasting in critical illness is associated with excess morbidity and mortality. Continuous feeding may suppress muscle protein synthesis as a result of the muscle-full effect, unlike intermittent feeding, which may ameliorate it. Does intermittent enteral feed decrease muscle wasting compared with continuous feed in critically ill patients? In a phase 2 interventional single-blinded randomized controlled trial, 121 mechanically ventilated adult patients with multiorgan failure were recruited following prospective informed consultee assent. They were randomized to the intervention group (intermittent enteral feeding from six 4-hourly feeds per 24 h, n = 62) or control group (standard continuous enteral feeding, n = 59). The primary outcome was 10-day loss of rectus femoris muscle cross-sectional area determined by ultrasound. Secondary outcomes included nutritional target achievements, plasma amino acid concentrations, glycemic control, and physical function milestones. Muscle loss was similar between arms (-1.1% [95% CI, -6.1% to -4.0%]; P = .676). More intermittently fed patients received 80% or more of target protein (OR, 1.52 [1.16-1.99]; P < .001) and energy (OR, 1.59 [1.21-2.08]; P = .001). Plasma branched-chain amino acid concentrations before and after feeds were similar between arms on trial day 1 (71 μM [44-98 μM]; P = .547) and trial day 10 (239 μM [33-444 μM]; P = .178). During the 10-day intervention period the coefficient of variation for glucose concentrations was higher with intermittent feed (17.84 [18.6-20.4]) vs continuous feed (12.98 [14.0-15.7]; P < .001). However, days with reported hypoglycemia and insulin usage were similar in both groups. Safety profiles, gastric intolerance, physical function milestones, and discharge destinations did not differ between groups. Intermittent feeding in early critical illness is not shown to preserve muscle mass in this trial despite resulting in a greater achievement of nutritional targets than continuous feeding. However, it is feasible and safe. ClinicalTrials.gov; No.: NCT02358512; URL: www.clinicaltrials.gov.

Sections du résumé

BACKGROUND
Acute skeletal muscle wasting in critical illness is associated with excess morbidity and mortality. Continuous feeding may suppress muscle protein synthesis as a result of the muscle-full effect, unlike intermittent feeding, which may ameliorate it.
RESEARCH QUESTION
Does intermittent enteral feed decrease muscle wasting compared with continuous feed in critically ill patients?
STUDY DESIGN AND METHODS
In a phase 2 interventional single-blinded randomized controlled trial, 121 mechanically ventilated adult patients with multiorgan failure were recruited following prospective informed consultee assent. They were randomized to the intervention group (intermittent enteral feeding from six 4-hourly feeds per 24 h, n = 62) or control group (standard continuous enteral feeding, n = 59). The primary outcome was 10-day loss of rectus femoris muscle cross-sectional area determined by ultrasound. Secondary outcomes included nutritional target achievements, plasma amino acid concentrations, glycemic control, and physical function milestones.
RESULTS
Muscle loss was similar between arms (-1.1% [95% CI, -6.1% to -4.0%]; P = .676). More intermittently fed patients received 80% or more of target protein (OR, 1.52 [1.16-1.99]; P < .001) and energy (OR, 1.59 [1.21-2.08]; P = .001). Plasma branched-chain amino acid concentrations before and after feeds were similar between arms on trial day 1 (71 μM [44-98 μM]; P = .547) and trial day 10 (239 μM [33-444 μM]; P = .178). During the 10-day intervention period the coefficient of variation for glucose concentrations was higher with intermittent feed (17.84 [18.6-20.4]) vs continuous feed (12.98 [14.0-15.7]; P < .001). However, days with reported hypoglycemia and insulin usage were similar in both groups. Safety profiles, gastric intolerance, physical function milestones, and discharge destinations did not differ between groups.
INTERPRETATION
Intermittent feeding in early critical illness is not shown to preserve muscle mass in this trial despite resulting in a greater achievement of nutritional targets than continuous feeding. However, it is feasible and safe.
TRIAL REGISTRY
ClinicalTrials.gov; No.: NCT02358512; URL: www.clinicaltrials.gov.

Identifiants

pubmed: 32247714
pii: S0012-3692(20)30584-5
doi: 10.1016/j.chest.2020.03.045
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02358512']

Types de publication

Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

183-194

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Auteurs

Angela S McNelly (AS)

William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; University College London (UCL), London, United Kingdom; National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at UCL Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: angela.mcnelly@qmul.ac.uk.

Danielle E Bear (DE)

Department of Nutrition and Dietetics, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Department of Critical Care, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; NIHR BRC, King's College London, London, United Kingdom.

Bronwen A Connolly (BA)

NIHR BRC, King's College London, London, United Kingdom; Lane Fox Clinical Respiratory Physiology Research Centre, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Gill Arbane (G)

Lane Fox Clinical Respiratory Physiology Research Centre, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Laura Allum (L)

Lane Fox Clinical Respiratory Physiology Research Centre, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Azhar Tarbhai (A)

University College London (UCL), London, United Kingdom.

Jackie A Cooper (JA)

University College London (UCL), London, United Kingdom.

Philip A Hopkins (PA)

Kings College Hospital, London, United Kingdom.

Matthew P Wise (MP)

University Hospital of Wales, Cardiff, Wales, United Kingdom.

David Brealey (D)

National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at UCL Hospitals NHS Foundation Trust, London, United Kingdom.

Kieron Rooney (K)

Bristol Royal Infirmary, Bristol, United Kingdom.

Jason Cupitt (J)

Blackpool Victoria Hospital, Blackpool, United Kingdom.

Bryan Carr (B)

University Hospitals of North Midlands, Stoke-on-Trent, United Kingdom.

Kiran Koelfat (K)

Department of Surgery and School of Nutrition and Translational Research in Metabolism (NUTRIM), University of Maastricht, Maastricht, The Netherlands.

Steven Olde Damink (SO)

Department of Surgery and School of Nutrition and Translational Research in Metabolism (NUTRIM), University of Maastricht, Maastricht, The Netherlands; Department of General, Visceral and Transplantation Surgery, RWTH University Hospital Aachen, Aachen, Germany.

Philip J Atherton (PJ)

Medical Research Council/Arthritis Research UK Centre for Musculoskeletal Aging, University of Nottingham, Nottingham, United Kingdom.

Nicholas Hart (N)

Lane Fox Clinical Respiratory Physiology Research Centre, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Hugh E Montgomery (HE)

University College London (UCL), London, United Kingdom; National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at UCL Hospitals NHS Foundation Trust, London, United Kingdom.

Zudin A Puthucheary (ZA)

Adult Critical Care Unit, Royal London Hospital, London, United Kingdom; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH